Short Interest in Marker Therapeutics, Inc. (NASDAQ:MRKR) Decreases By 18.6%

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the recipient of a significant drop in short interest in November. As of November 15th, there was short interest totalling 57,000 shares, a drop of 18.6% from the October 31st total of 70,000 shares. Approximately 0.9% of the company’s stock are short sold. Based on an average daily volume of 36,200 shares, the short-interest ratio is currently 1.6 days.

Marker Therapeutics Stock Up 9.7 %

Shares of MRKR stock opened at $3.50 on Monday. The stock’s 50-day moving average is $3.35 and its 200 day moving average is $3.85. Marker Therapeutics has a 1-year low of $2.44 and a 1-year high of $6.16.

Wall Street Analysts Forecast Growth

Separately, LADENBURG THALM/SH SH boosted their price objective on shares of Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, October 21st.

Institutional Trading of Marker Therapeutics

A hedge fund recently bought a new stake in Marker Therapeutics stock. Invst LLC bought a new stake in Marker Therapeutics, Inc. (NASDAQ:MRKR) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 20,000 shares of the company’s stock, valued at approximately $56,000. Invst LLC owned approximately 0.22% of Marker Therapeutics as of its most recent SEC filing. 22.39% of the stock is currently owned by institutional investors and hedge funds.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.